Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Caffeine Tablet Clear all
Completed Phase 2 Interventional

Efficacy of a Self-advocacy Serious Game Intervention

NCT04813276
View directory record Official record
Conditions
Self-Management, Quality of Life
Interventions
Strong Together serious game, Enhanced Care as Usual
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Influence of Lifestyle Factors on Neutrophil Migration Pilot Study

NCT02411318
View directory record Official record
Conditions
Neutrophil Chemotactic Response
Interventions
Exercise, ProLab 200mg caffeine capsule, Ethanol ingestion, Glucose Tolerance Drink
Behavioral · Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 2, 2026, 1:33 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI

NCT06763172
View directory record Official record
Conditions
Healthy, Caffeine, Adenosine, Dopamine D2/3 Receptor Availability
Interventions
Caffeine (200 mg), Placebo
Drug
Lead sponsor
Hsiao-Ying Wey
Other
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain

NCT01929031
View directory record Official record
Conditions
Pain, Postoperative, Tooth Diseases
Interventions
ibuprofen + caffeine, ibuprofen, caffeine, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants

NCT06215430
View directory record Official record
Conditions
Healthy
Interventions
Caffeine Tablet, Omeprazole capsule, Warfarin tablet, Pirtobrutinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 2, 2026, 1:33 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Pain Management After Shoulder Arthroplasty

NCT04872270
View directory record Official record
Conditions
Caffeine, Pain, Joint
Interventions
Total Shoulder Arthroplasty, Caffeine Pill, Percocet 10Mg-325Mg Tablet, Zofran 4Mg Tablet
Procedure · Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
55 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 1 Interventional

A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

NCT02655614
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
GDC-0134, Placebo, Rabeprazole, Midazolam, Caffeine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
San Francisco, California • Jacksonville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 2, 2026, 1:33 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

NCT03358706
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Ustekinumab IV Infusion, Ustekinumab SC Injection, Midazolam 2 mg, Warfarin 10 mg, Vitamin K 10 mg, Omeprazole 20 mg, Dextromethorphan 30 mg, Caffeine 100 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
3
States / cities
Cypress, California • Miami Springs, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Sep 2, 2026, 1:33 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Caffeine Consumption in Glaucoma Patients and Healthy Subjects

NCT03675412
View directory record Official record
Conditions
Glaucoma, Primary Open Angle
Interventions
Caffeine tablet
Dietary Supplement
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Interaction of Caffeine and Hydration on Voice

NCT01435837
View directory record Official record
Conditions
Voice Disorders
Interventions
C2 (200mg of caffeine; 1/2 L of water), C3(200mg of caffeine; 1 L of water), C1 (200mg of caffeine, no water), Placebo (no caffeine, no water).
Drug
Lead sponsor
Southern Illinois University Carbondale
Other
Eligibility
18 Years to 35 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Carbondale, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Efficacy of ONE A DAY Weightsmart Advanced Versus Caffeine and Placebo on Energy Expenditure, Thermogenesis and Perceived Energy Levels in Women.

NCT00781586
View directory record Official record
Conditions
Energy Expenditure
Interventions
One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350), Caffeine, Placebo
Dietary Supplement · Drug
Lead sponsor
Bayer
Industry
Eligibility
25 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 2, 2026, 1:33 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

NCT04764851
View directory record Official record
Conditions
Drug-Interactions
Interventions
ecopipam HCl ~2mg/kg/day, Cohort 1 Probe Cocktail, Cohort 2 Probe Cocktail, Cohort 3 Probe Cocktail
Drug · Combination Product
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Sep 2, 2026, 1:33 AM EDT
Terminated No phase listed Observational Results available

Risk Stratification and Early Alerting Regarding COVID-19 Hospitalization

NCT04709068
View directory record Official record
Conditions
Covid19
Interventions
Current Health
Device
Lead sponsor
Current Health
Industry
Eligibility
21 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Effect of Tablet Size on Cognitive Performance Caffeine

NCT03694886
View directory record Official record
Conditions
Placebo Effect
Interventions
Caffeine Anhydrous with small sucrose pill, Placebo - large sucrose pill, Caffeine Anhydrous with large sucrose pill, Placebo - small sucrose pill
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Sep 2, 2026, 1:33 AM EDT
Not listed Not applicable Interventional

Caffeine Study for Pain Control Following Total Joint Replacement

NCT04280263
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Caffeine, Placebo oral tablet
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Egg Harbor, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 1 Interventional

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

NCT01517399
View directory record Official record
Conditions
Solid Tumors
Interventions
tivantinib, omeprazole, s-warfarin, caffeine, vitamin K, digoxin, midazolam
Drug · Dietary Supplement
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Caffeine/Propranolol Intervention for Acute Migraine

NCT01080677
View directory record Official record
Conditions
Migraine Disorders
Interventions
caffeine/propranolol combination tablet, placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Sep 2, 2026, 1:33 AM EDT
Recruiting Phase 1 Interventional

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

NCT05176483
View directory record Official record
Conditions
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI)
Interventions
Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
1,394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction (DDI) Study for TD-9855

NCT03432793
View directory record Official record
Conditions
Drug Drug Interaction (DDI)
Interventions
TD-9855, Fluvoxamine, Itraconazole, Caffeine
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Sep 2, 2026, 1:33 AM EDT
Active, not recruiting Phase 2 Interventional

REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy

NCT01984138
View directory record Official record
Conditions
Estrogen Receptor Positive Breast Cancer, Breast Cancer
Interventions
ESTRING, Replens, Vagifem
Drug
Lead sponsor
Polly A. Niravath, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effect of Fasting and Exercise on Uptake of Tc-99m Sestamibi in Breast Tissue

NCT01944215
View directory record Official record
Conditions
Molecular Imaging
Interventions
Meal, Exercise, Sestamibi, Caffeine Tablet, External Heating
Dietary Supplement · Other · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 2, 2026, 1:33 AM EDT
Terminated Not applicable Interventional Results available

Innovative Care of Older Adults With Chronic Heart Failure: A Comparative Effectiveness Clinical Trial (I-COACH)

NCT04304833
View directory record Official record
Conditions
Heart Failure
Interventions
Provider-Based Care Model Arm, mHealth Model Arm
Other · Behavioral
Lead sponsor
University of Arkansas
Other
Eligibility
55 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy Participants

NCT04655040
View directory record Official record
Conditions
Healthy Participants
Interventions
Caffeine, Ritlecitinib
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Sep 2, 2026, 1:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Xofluza-Wearables Feasibility-Study

NCT06161454
View directory record Official record
Conditions
Infection, Coronavirus, Infections, Influenza, Transplant, Infection Viral
Interventions
Baloxavir Marboxil
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years and older
Enrollment
498 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Sep 2, 2026, 1:33 AM EDT